AQEMIA is a drug invention company developing novel molecules to address unmet medical needs. Its proprietary QEMI platform combines over a decade of physics-based research with state-of-the-art generative AI, enabling the rapid design of drug candidates without relying on experimental training data.

By leveraging its unique fast physics engine, the company reconciles speed and precision in molecular design, unlocking large-scale exploration of previously inaccessible chemical space. Aqemia’s portfolio spans oncology, immunology and neurology, and includes both wholly owned programs and partnered programs with leading pharmaceutical companies, such as a multi-year, $150M strategic collaboration with Sanofi.

The company’s most advanced preclinical programs are currently undergoing in vivo optimization, demonstrating superior efficacy in animal models.

Headquartered in Paris with an office in London, AQEMIA employs around 70 people and has raised over $100 million since its inception.

NETRI is an innovative industrial TechBio whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-Sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology, immunology, neurological disorders, neurotoxicity and dermatology.

Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world-first compartmentalized electrophysiology platform in standard 96-well plate format – NeuroFluidics™ MEA – which acts as a data generation hub for its Digital Signature libraries of tested and reference compounds. To enable the prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, organ-on-chip hardware, AI-trained software, digital libraries and methods.

NETRI provides two types of offers:
Standard Microphysiological Systems (MPS)
NETRI’s MPS can be acquired with cells & cell reagents, scaffolds and software for R&D groups interested in:
• 3D ECM Matrix for primary or hiPSC-derived organoids and tumoroids (liver, pancreatic carcinoma, adipose tissues, brain).
• Compartmentalized barrier for innervation and vascularization of 3D hiPSC cell cultures, including multi-organoid systems.
• Compartmentalized electrophysiology for co-culture of 2D and 3D CNS or PNS cells, co-culture of neurons and skin cells and neuromuscular junction.

The Neuron-as-a-Sensor (NaaS) platform includes devices, cells & reagents, software (analytics, Digital Signature generation and access to the Digital Library), and the full NaaS methodology. Among others, this platform can be applied to the following applications:
• Drug-induced peripheral neuropathies, including CIPN, for which NETRI is currently establishing a ring trial with 6 major pharmaceutical companies and a world-leading CRO to assess inter-site reproducibility before regulatory submission of the methodology for this context of use
• General CNS neurotoxicity (pharma)
• Skin model (pruritus)
• Inflammatory pain
• Drug-induced seizure
• ALS (motor only)
• General CNS neurotoxicity (chemicals, pesticides)
• DPN (diabetic peripheral neuropathy)
• Emetic and nausea response

NETRI ultimately aims to license its technology for on-premises deployment for internal decision-making and inclusion in regulatory submissions.

bYoRNA is developing a disruptive, patented technology for producing messenger RNA (mRNA) via yeast fermentation, an alternative to the current in vitro transcription (IVT) process. This approach will significantly reduce the immunogenicity of the mRNAs produced, improve their efficiency while allowing for better tissue targeting and diminishing the production cost by two orders of magnitude.

They can produce 10,000-nucleotide mRNA as easily as 4,000-nucleotide mRNA, with neither dsRNA nor fragments, due to the yeast built-in quality control machinery.

Over the past six months, bYoRNA has achieved the necessary productivity and purity levels for testing in cell and animal models. Current work focuses on validating the biological quality of the produced mRNAs, with results expected by mid-2026 in cell models (protein expression and functionality) and then in animal models (tolerance and biological activity).

They have raised $10M+ in dilutive and non-dilutive funding and secured partnerships for proof-of-concepts on 3 critical indications with TRON, the mRNA research institute created by the founders of BIONTECH, as well as a leading animal pharma company and a major European rare disease institute.

This milestone, crucial for demonstrating the quality of their mRNAs compared to those produced by IVT, will enable them to launch their Series A funding round with a target amount of $12 million. This funding will accelerate the scaling up of the fermentation process, industrialize the purification steps, produce pilot batches compliant with pre-GMP requirements, and initiate initial industrial collaborations with biotechnology and pharmaceutical companies.

Ultimately, the technology developed aims to become an industrial platform supporting the development of innovative vaccines and therapies, while reducing the costs and production times associated with current technologies.